Protagonist Therapeutics (PTGX) stock broke out Monday after the company's Johnson & Johnson (JNJ)-partnered drug topped its rival from Bristol Myers Squibb (BMY) in a study of plaque psoriasis patients.
↑ X NOW PLAYING How To Buy Stocks: Spotting Early Entries On Potential BreakoutsProtagonist and J&J pitted their experimental drug, icotrokinra or JNJ-2113, against Bristol's approved treatment, Sotyktu. In addition to showing statistically significant results on the primary goals of the study — improvement in inflammation and reaching clear skin — icotrokinra outperformed Sotyktu across all study goals at weeks 16 and 24.
Now, J&J is planning a head-to-head study comparing the same drug in patients to its own Stelara in patients with plaque psoriasis. This suggests "JNJ's strong confidence in JNJ-2113's efficacy as well as commitment to establishing JNJ-2113 as a paradigm shifting therapy in PsO, and potentially additional indications as well," Wedbush analyst Yun Zhong said in a report.
Protagonist Therapeutics shares shot up more than 30% to 50.03 in early action. Shares opened north of a buy point at 48.89 out of a consolidation, according to MarketSurge.
More to follow.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.
Why Moderna Stock Has Surged 15% This Week Despite Mixed News
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
Get Timely Buy & Sell Alerts With IBD Leaderboard
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。